Challenging treatment of bilateral multiple infection panuveitis in HIV/AIDS patients

Widya Artini¹,², Soedarman Sjamsoe¹,², Made Susiyanti¹,²

¹Department of Ophthalmology, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia
²Jakarta Eye Center, Jakarta 10430, Indonesia

Correspondence to: Widya Artini. Jl. Tanjung No. 2 Menteng, Jakarta 10430, Indonesia. ikkesumantri@gmail.com

Received: 2017-08-23        Accepted: 2018-01-26

DOI:10.18240/ijo.2018.06.28


Dear Editor,

I, Dr. Widya Artini from the Department of Ophthalmology, Faculty of Medicine University of Indonesia, Cipto Mangunkusumo Hospital, would like to submit two case reports on bilateral panuveitis in patients with human immunodeficiency virus (HIV) /acquired immune deficiency syndrome (AIDS).

There has been a gradual increase in the number of HIV-positive patients in Indonesia. It was estimated that there were approximately 697,000 people living with HIV in 2016, and it is assumed that the number will increase gradually over the next years by up to 11.6% [1]. Previous studies have reported that the prevalence of HIV-induced uveitis in the AIDS population was 4% [2-4]. Ocular opportunistic infections are most frequently associated with cytomegalovirus (CMV), syphilis and tuberculosis (TBC) infections in patients with HIV [5-7]. Ocular infection of both syphilis and CMV infections in HIV patients may manifest as panuveitis. We have therefore presented here two cases with similar HIV-related panuveitis managed with timely and thorough investigations which successfully prevented the patients’ loss of vision.

Case 1

A 65-year-old Malay male, complained of acute blurred vision in his right eye during the last week of October 2015. We had no previous record of his ocular history. The patient was known to have a history of controlled arthritis which commenced 5y ago, also of condyloma acuminatum, which was treated 3y ago with the oral antiviral (gancyclovir). An eye examination revealed that his visual acuity was 1/300 with intraocular pressure (IOP) of 30 mm Hg in the right eye, while in the left eye, his visual acuity was 6/9 with IOP of 14 mm Hg. Slit lamp examination of the right eye revealed conjunctival injection and clear cornea with several round, fine keratic precipitates in the centre of the cornea. It also showed the anterior chamber with cells grade 2 and flare grade 2, posterior synechia, and an immature cataract of the nuclear lens LOCH2 (Figure 1). Examination of the right retina revealed a cloudy vitreous and hazy finding. No inflammation was found in the left eye, however, an immature cataract was detected and the fundus showed that the cup-to-disc ratio was 0.3, while the retinal vascular was within normal limits. Gonioscopy showed that the anterior chamber angle was open in both eyes, while ultrasonography revealed mild haziness (Figure 2). The patient was diagnosed with panuveitis, ocular hypertension of the right eye and cataracts in both eyes.

The right eye was treated with corticosteroid eye drops (prednisolone acetate 1%) every three hours, to control inflammation, beta blocker eye drops (timolol 0.5%) and brinzolamide eye drops twice per day. Oral medication, methylprednisolone 16 mg twice per day was also recommended. Routine blood tests were performed, including TORCH and immunological blood tests for HIV. Chest X-ray, ear, nose, throat (ENT) examination, and immunological and internal medical examinations were also carried out.

On the 5th day, the patient complained that he had lost the vision in both eyes and an eye examination revealed that the visual acuity of both his right and left eyes was 1/300. The IOP were 18 mm Hg (OD) and 15 mm Hg (OS). Results of a biomicroscopy examination of both eyes complied with the results of the previous examination of his right eye, i.e. there was no improvement detected on his right eye. Fundus examination of both eyes showed hazy vitreous and the retina was cloudy. Paracentesis was performed for polymerase chain reaction (PCR) analysis to detect viral DNA in the aqueous humor of the right eye. During treatment, the patient experienced a viral rash all over his body. The patient returned for a follow-up visit three days later and both the TORCH blood test and HIV test showed positive results. Results also showed high levels of IgM and IgG CMV antibodies. CMV vitreous tap result was also positive with CD4 cell count of
160 cells/µL. A diagnosis of panuveitis caused by CMV and HIV was further established. Additional oral treatment was provided using valganciclovir (valcyte®) with an initial dose of 900 mg daily for three weeks along with highly active antiretroviral therapy (HAART) to suppress HIV infection. Oral steroid was discontinued, however, the application of eye drops was continued.

Three weeks following the HAART and antiviral treatment, improvement was seen in both eyes. Visual acuity in his right eye was 6/40 with an IOP of 14 mm Hg, while the visual acuity of his left eye was 6/12 with an IOP of 14 mm Hg. Biomicroscopic examination showed a healthy conjunctiva and clear cornea with no cell or flare detected in the anterior chamber. The fundus became clear and cup-to-disc ratio was 0.4 without nasализation. Optical coherence tomography (OCT) examination showed cystoids macular edema (Figure 3). Eye drop steroid medication was reduced to four times per day and timolol treatment discontinued. Nevertheless, valganciclovir was continued at a dose of 450 mg twice per day for a further 20mo. Visual acuity of the right eye remained at 6/40 and in the 3rd month, cataract surgery was performed with good results. The visual acuity improved to 6/7.5, while visual acuity of the left eye returned to 6/7.5. The patient continued with maintenance therapy using efavirenz®, lamivudine® and tenofovir® medications. Panuveitis regressed up to the 20th month follow-up with no flare-up and a CD4 cell count of 500 cells/µL.

Case 2

A 47 year old married Malay male patient who complained of worsening blurred vision in both eyes commencing approximately two months before admission. One year prior to the first hospital visit, the patient complained of an intermittent episode of seeing black spots in his left eye. The patient was known to have a history of promiscuity and tattoos. An ophthalmologic examination showed that his visual acuity was 1/60 for both eyes. It also showed cells +3 and flare +3 in the anterior chamber without posterior synechia, with positive papillary light reflex in both eyes. Funds examination revealed hazy vitreous, and other detailed structures of the retina were only superficially examined (Figure 4). The diagnosis showed posterior uveitis in both eyes due to suspected toxoplasma, CMV, syphilis infections and/or AIDS. Further laboratory investigation for uveitis was planned for the patient. The laboratory examination demonstrated a positive result for the HIV test, with negative results for IgG and IgM anti-
toxoplasma antibodies; negative results for IgG and IgM anti-
herpes simplex virus (HSV) 1 antibodies, positive results
for IgG and IgM anti-HSV 2 antibodies, positive result on
syphilis serology tests (treponema pallidum haemagglutination
assay and fluorescent treponemal antibody-absorbed test),
positive result for IgG anti-CMV antibody, negative result for
IgM anti-CMV antibody and CD4+ T-lymphocyte cell count
was 261 cells/mL. Chest X-ray and Mantoux test showed no
abnormalities. The patient was examined by both a dermato-
venerologist and an internist and was diagnosed with posterior
uveitis in both eyes caused by syphilis.
He was treated with benzathine penicillin 2.4 million units
twice a day with an interval of 1wk apart. The patient was also
treated with duviral® 1 tablet daily (zidovudine® 300 mg and
lamivudine® 150 mg) and efavirenz® 600 mg daily; HAART
therapy was also started, followed by oral steroid treatment
for 3d. After 1wk, revealed improvement in anterior segment,
however from posterior examination on both eyes still showed
dense vitreous opacity due to severe inflammation (Figure 5).
In the following 2wk, his visual acuity was 6/20 for the right
eye and 6/18 for the left eye. No cells or flare could be found
in the anterior chamber of either eye. The vitreous was clear
and the fundus showed no exudates or bleeding, however,
there was dilatation of retinal vascular and disc pallor of
optic nerve head (Figure 6). The systemic medical treatment
were continued for several weeks, and after 3mo there was
significant improvement on both eyes with visual acuity of
the right eye was 6/7.5 and 6/9 on the left eye. Anterior and
posterior segments showed clear condition on both eyes
(Figures 7, 8).
We were able to determine from these two cases that ocular
manifestation should be taken into account whenever treating
HIV/AIDS patients with possible opportunistic infection.
Panuveitis is the earliest ocular manifestation found in
patients with AIDS[3]. It should be noted that uveitis in
patients presenting with HIV/AIDS may be more severe than
in those with other infections, and may also result in greater
sequelae. Previous studies have shown that HIV is a common
co-infection of multiple ocular tissues, such as the retina,
conjunctiva, cornea and iris of patients with AIDS[3,7-8]. It has
been also reported that the HIV virus is able to replicate in
CD4-positive T lymphocytes, macrophages, endothelial cells,
dendritic cells, monocytes, astrocytes and microglial cells[9].
Kunavisarut et al[8] have noted that panuveitis may occur in
patients presenting with HIV without any other opportunistic
infection. It may appear as a mild inflammatory reaction in
the anterior chamber with detected HIV-1 RNA in intraocular
fluid. Panuveitis may not always be severe nor show sudden
symptoms or acute signs. Therefore, progress may well
exacerbate unnoticed.
It has been reported that improved immune function may
occur after completing HAART thus altering inflammatory
response in eye tissues\textsuperscript{[3,10-11]}. However, in cases with proven opportunistic infection, the underlying cause must be treated immediately with utmost care using the combined HAART treatment. Improvement of inflammation should ensue rapidly and the visual acuity restored significantly.

The first patient in this case presented with infection in both eyes. There was a moderate anterior inflammatory symptom in both eyes and several inflammatory cells within the anterior chamber. In the second case, there were similar clinical manifestations and differentiation of the cause of opportunistic infection was rendered difficult since there were no characteristic symptoms. Both cases had no previous history of HIV infection or HAART. Therefore, it was essential to perform a thorough blood serologic test to determine viral or other infections featuring in all cases with panuveitis. It is also recommended to include humor aqueous tap for PCR analysis to detect viral DNA or other infections in order to unambiguously identify the definitive cause\textsuperscript{[12]}

In the first case presented by HIV/AIDS patient with CMV-associated uveitis, steroid treatment was ceased and substituted with oral gancyclovir and intravitreous injection of antiretroviral to overcome further severe inflammatory reaction in the posterior segment. Oral treatment alone often exerts no significant response. Oral treatment was given for 20mo in order to suppress CMV replication and, thus, prevent relapse and prolonged CMV infection. The oral treatment was combined with HAART to suppress HIV replication in peripheral blood and increase the number of CD4+ T lymphocyte cells. This should subsequently result in improvement of the immune system\textsuperscript{[9,11]}. Jabs et al\textsuperscript{[3]} have reported that combined treatment using long-term modern antiretroviral (HAART) for HIV/AIDS patients with CMV-associated retinitis may bring about immune recovery reaction uveitis (IRU) and the incidence of immune recovery uveitis was 2.2/100 person-years (PYs).

Patients without immune recovery had a mortality of 44.4/100 PYs following diagnosis of CMV retinitis, whereas those with immune recovery had a mortality of 2.7/100 PYs ($P<0.001$). Therefore, it can be concluded that HAART treatment is absolutely essential\textsuperscript{[9]}. It is also important to notice that CMV infection is associated with a 60% increase in mortality among persons living with AIDS\textsuperscript{[9,13-14]}. Moreover, higher CMV loads are usually associated with greater risks of mortality\textsuperscript{[15-16]}. Our cases suggest that HAART treatment without anti-CMV treatment may bring about delayed recovery. Therefore, a long-term additional systemic anti-CMV treatment is essential, resulting in a better outcome than repetitive intravitreous injections to prevent recurrent vitritis and retinitis. Due to the nature of systemic infection, the propensity of CMV to transactivate HIV and CMV’s own intrinsic immunosuppressive effect, systemic treatment that inhibits CMV replication may well improve immune function and survival of patients\textsuperscript{[11,13,16-18]}

Once sustained immune recovery has been adequately reached, the specific immunity against CMV is then restored. The parameter requires a minimum of 150 absolute CD4+ T lymphocytes/mL detected in the blood stream and the replication of CMV can be controlled by the immune system. Therefore, anti-CMV therapy is no longer necessary\textsuperscript{[11,19]}. Intravitreous injection of anti-CMV may be needed in the case that vitritis occurs. However, the treatment is only administered when there is an indication\textsuperscript{[11]}

In the second case, optimal intensive treatment for syphilis infection was administered, either by intramuscular injection or oral treatment along with immediate HAART treatment. Routine tests should be recommended for HIV-related syphilis infections as HIV infection is strongly correlated to the reemergence of infectious syphilis and increased risk of neurosyphilis. In addition to panuveitis, the most common ocular manifestation may include peripheral retinitis or necrotizing retinitis that usually causes diagnostic confusion with acute retinal necrosis resulting from CMV retinitis\textsuperscript{[13]}

A multidisciplinary approach is recommended by collaborating with a genitourinary physician who can provide combined treatment for treating the systemic infection, including HIV. Moreover, additional treatment using oral prednisolone at a dose of 60 mg daily for 3d may improve the healing process of retinitis. The condition often resolves within 3-4d, resulting in typical sequelae of retinal pigment epithelial atrophy\textsuperscript{[7]}. The sequelae has also been reported in our cases, i.e. the fundus became clear and retinal abnormality appeared. Hughes et al\textsuperscript{[7]} have also reported that there is a strong correlation between HIV co-infection and syphilitic retinitis, found in 100% of HIV-infected patients. They have also reported that panuveitis is not an early clinical manifestation of HIV infection.

The common complications that occur in all cases of patients with HIV-related panuveitis are secondary glaucoma, ocular hypertension, cataracts, cystoid macular edema, epiretinal membrane formation, visual impairment and blindness. An intensive follow-up and multidisciplinary approach in collaboration with internists and venereologists will bring about optimal outcomes. Long-term ocular and systemic follow-up is mandatory as a relapse or re-infection may occur.

In conclusion, timely and appropriate treatment is essential in the management of patients with bilateral panuveitis and opportunistic HIV infections. A routine test consists of a complete serologic blood test, HIV test, Mantoux tuberculin skin test and chest X-ray, all of which should be performed for each patient presenting with uveitis. Moreover, a multidisciplinary approach to manage the underlying cause is of utmost significance. Early diagnosis and timely treatment using combined HAART and therapy for opportunistic infections may result in a substantial recovery in visual acuity.
ACKNOWLEDGEMENTS

Authors’ contributions: Artini W encountered the first patient and collaborated with Sjamsoe S in handling the comprehensive management of the patient. Susiyanti M encountered the second patient and was responsible for the overall therapy. All authors participated in the compilation of this manuscript.

Conflicts of Interest: Artini W, None; Sjamsoe S, None; Susiyanti M, None.

REFERENCES

14 Ahmed I, Al E, Chang E, Lucky A. Ophthalmic manifestations of HIV. Available at: http://hivinsite.ucsf.edu/InSite?page=kb-04-01-12.